Smith & Nephew SNATS, Inc. (NYSE:SNN) Short Interest Update

Smith & Nephew SNATS, Inc. (NYSE:SNN) saw a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 3,099,615 shares, a decrease of 15.8% from the January 29th total of 3,681,058 shares. Based on an average trading volume of 910,459 shares, the days-to-cover ratio is presently 3.4 days. Approximately 0.7% of the company’s stock are sold short. Approximately 0.7% of the company’s stock are sold short. Based on an average trading volume of 910,459 shares, the days-to-cover ratio is presently 3.4 days.

Hedge Funds Weigh In On Smith & Nephew SNATS

Several institutional investors and hedge funds have recently modified their holdings of SNN. Bank of Montreal Can grew its holdings in Smith & Nephew SNATS by 321.6% during the second quarter. Bank of Montreal Can now owns 3,429,829 shares of the medical equipment provider’s stock worth $105,056,000 after acquiring an additional 2,616,301 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Smith & Nephew SNATS by 6,663.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock worth $37,082,000 after purchasing an additional 1,192,755 shares during the period. ABC Arbitrage SA increased its holdings in shares of Smith & Nephew SNATS by 1,063.4% during the 2nd quarter. ABC Arbitrage SA now owns 898,635 shares of the medical equipment provider’s stock valued at $27,525,000 after purchasing an additional 821,393 shares in the last quarter. Todd Asset Management LLC acquired a new position in shares of Smith & Nephew SNATS in the 3rd quarter valued at $26,319,000. Finally, Goldman Sachs Group Inc. boosted its holdings in Smith & Nephew SNATS by 49.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after buying an additional 583,809 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew SNATS Stock Performance

Shares of NYSE SNN traded down $0.35 during midday trading on Wednesday, reaching $36.40. The company had a trading volume of 1,191,926 shares, compared to its average volume of 943,798. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a 1 year low of $23.91 and a 1 year high of $38.79. The business’s 50-day simple moving average is $34.29 and its 200 day simple moving average is $34.94.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SNN. Royal Bank Of Canada cut shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. Kepler Capital Markets raised Smith & Nephew SNATS to a “strong-buy” rating in a research report on Monday, November 17th. Canaccord Genuity Group dropped their price objective on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a research report on Tuesday, November 11th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st. Finally, Wall Street Zen lowered shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. One research analyst has rated the stock with a Strong Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Smith & Nephew SNATS presently has a consensus rating of “Hold” and a consensus price target of $35.75.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.